Valuation: Lundbeck

Market Cap 51.05B 7.65B 6.83B 6.31B 5.72B 10.7B 726B 10.87B 75.92B 30.06B 380B 28.7B 28.09B 1,199B P/E 2026 *
11.3x
P/E 2027 * 11.2x
Enterprise Value 54.98B 8.24B 7.36B 6.79B 6.16B 11.52B 782B 11.71B 81.77B 32.37B 410B 30.91B 30.25B 1,292B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.94x
Free-Float
30.74%
Yield 2026 *
3.02%
Yield 2027 * 2.71%
1 day-0.97%
1 week+9.24%
Current month+14.87%
1 month+11.86%
3 months+35.31%
6 months+39.74%
Current year+35.50%
1 week 44.9
Extreme 44.9
49.8
1 month 41.05
Extreme 41.05
49.8
Current year 31.4
Extreme 31.4
49.8
1 year 31.4
Extreme 31.4
49.8
3 years 23.3
Extreme 23.3
49.8
5 years 21.94
Extreme 21.935
49.8
10 years 21.94
Extreme 21.935
49.8
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 67 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%+9.24% - - 7.65B
+0.23%+2.93%+54.48%+124.72% 1,135B
+0.79%+4.88%+39.87%+78.63% 635B
+0.34%+1.36%+25.65%+97.33% 505B
+1.45%+4.21%+48.13%+66.95% 378B
-2.24%-1.29%+61.11%+34.32% 358B
-0.55%+2.35%+23.23%+49.39% 295B
-0.04%+3.37%+2.17%+23.34% 266B
+0.27%+3.90%+51.64%+63.70% 237B
+1.54%+3.53%+31.54%+101.87% 193B
Average +0.05%+1.60%+37.54%+71.14% 444.85B
Weighted average by Cap. +0.17%+1.63%+41.47%+83.40%

Financials

2026 *2027 *
Net sales 25.94B 3.89B 3.47B 3.21B 2.91B 5.44B 369B 5.53B 38.58B 15.27B 193B 14.58B 14.27B 609B 26.21B 3.93B 3.51B 3.24B 2.94B 5.49B 373B 5.58B 38.99B 15.43B 195B 14.74B 14.42B 616B
Net income 4.62B 692M 618M 571M 517M 968M 65.68B 984M 6.87B 2.72B 34.41B 2.6B 2.54B 108B 4.66B 698M 623M 576M 522M 976M 66.27B 992M 6.93B 2.74B 34.72B 2.62B 2.56B 109B
Net Debt 3.93B 589M 526M 486M 440M 824M 55.91B 837M 5.85B 2.31B 29.29B 2.21B 2.16B 92.35B -218M -32.67M -29.17M -26.95M -24.42M -45.69M -3.1B -46.45M -324M -128M -1.62B -123M -120M -5.12B
Projected Income Statement - Annual - Lundbeck
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
26-10-26 DKK 49.05 -0.10% 65,228
26-10-23 DKK 49.10 +1.87% 58,747
26-10-22 DKK 48.20 +2.88% 41,925
26-10-21 DKK 46.85 +1.30% 67,329
26-10-20 DKK 46.25 +3.01% 96,761
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Lundbeck
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
52.10DKK
Average target price
50.96DKK
Spread / Average Target
-2.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lundbeck